SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : BEAT THE S&P - with Momentum, High Growth, High Earnings -- Ignore unavailable to you. Want to Upgrade?

To: Stock Watcher who wrote (38)12/11/1998 1:03:00 PM
From: Captain Ed  Read Replies (1) | Respond to of 302
 
DRAXF is running...canine drug approved in US + BIG Pfizer deal

Including not only a $10 million payment this year, but royalties beyond that. Also, reported earlier that the company has had 6 consecutive quarters of 50%+ revenue growth.

Will move once the word gets out.

Ed



To: Stock Watcher who wrote (38)12/11/1998 1:46:00 PM
From: TradeOfTheDay  Read Replies (2) | Respond to of 302
 
Hi AV,
I do like OMKT - expected 45% growth. Price/Sales is lower than some in their group - 8.8 (esp ATHM @ 881!and EBAY @ 1,254) . Just for comparison sake, CSC has a P/S of 1.63 but expected growth of only 17%. The analysts are hanging back on endorsing OMKT though and I don't understand why - 7 have it on hold... they must see something - admittedly their earnings growth looks good.

Bev


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News